The Short Communication by Burkhard Otremba, Jens Borchardt, Andra Kuske, Maike Hollngel-Schmitz & Florian O Losch, ‘Real-world use and acceptance of rituximab biosimilars in non-hodgkin lymphoma in an oncologist network in Germany’, which appeared in the May 2020 issue of Future Oncology 16(15), 1001–1012, was published with an error in . The corrected figure is included below.
DLBCL: Diffuse large B-cell lymphoma; ICD: World Health Organisation International Classification of Diseases; NHL: Non-Hodgkin Lymphoma; NK: Natural killer; MCL: Mantle cell Lymphoma; MZL: Marginal zone lymphoma.
![Figure 1. Distribution of patients included in the database according to the International Classification of Diseases code indication.DLBCL: Diffuse large B-cell lymphoma; ICD: World Health Organisation International Classification of Diseases; NHL: Non-Hodgkin Lymphoma; NK: Natural killer; MCL: Mantle cell Lymphoma; MZL: Marginal zone lymphoma.](/cms/asset/818e2ced-d709-423a-8a83-2d2d51d478fb/ifon_a_12332873_f0001.jpg)
The authors and editors of Future Oncology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.